• Home
  •  / Taysha Gene Therapies

Taysha Gene Therapies

  • Market Capitalization$176 M2022-08-04

OverviewSuggest Edit

Taysha Gene Therapies is a biotechnology company. It develops treatments to eradicate monogenic diseases of the central nervous system (CNS).
TypePublic
Founded2020
HQDallas, TX, USMap
Websitetayshagtx.com
View Jobs

Recent NewsAll News

Latest Updates

Share Price (Aug 2022)$4.3(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Taysha Gene Therapies

RA Session II

RA Session II

President, Founder and CEO
Phillip B. Donenberg

Phillip B. Donenberg

Director
Kamran Alam

Kamran Alam

Chief Financial Officer
Sukumar Nagendran

Sukumar Nagendran

Director
Paul B. Manning

Paul B. Manning

Director
Suyash Prasad

Suyash Prasad

Chief Medical Officer and Head of Research and Development
Show more

Taysha Gene Therapies Office Locations

Taysha Gene Therapies has an office in Dallas
Dallas, TX, US (HQ)
3000 Pegasus Park Dr Suite 1430
Show all (1)

Taysha Gene Therapies Financials and Metrics

Taysha Gene Therapies Revenue

USD

Net income (FY, 2020)

(60.0m)

EBIT (FY, 2020)

(43.0m)

Market capitalization (4-Aug-2022)

176.0m

Closing stock price (4-Aug-2022)

4.3

Cash (31-Dec-2020)

251.3m
Taysha Gene Therapies's current market capitalization is $176 m.
Annual
USDFY, 2019FY, 2020

General and administrative expense

128.0k11.1m

R&D expense

987.0k31.9m

Operating expense total

1.1m43.0m

EBIT

(1.1m)(43.0m)
Half Year
USDH1, 2020

General and administrative expense

1.0m

R&D expense

8.6m

Operating expense total

9.6m

EBIT

(9.6m)
Quarterly
USDQ3, 2020

General and administrative expense

4.0m

R&D expense

11.1m

Operating expense total

15.0m

EBIT

(15.0m)
show all
Annual
USDFY, 2019FY, 2020

Cash

251.3m

Prepaid Expenses

6.6m

Current Assets

15.0k257.9m

PP&E

287.0k
Quarterly
USDQ2, 2020Q3, 2020

Cash

11.2m278.6m

Prepaid Expenses

9.0k604.0k

Current Assets

11.3m279.2m

PP&E

19.0k28.0k
show all
Annual
USDFY, 2019FY, 2020

Net Income

(1.1m)(60.0m)

Depreciation and Amortization

9.0k

Accounts Payable

(6.6m)

Cash From Operating Activities

(30.7m)
Quarterly
USDQ2, 2020Q3, 2020

Net Income

(26.7m)(41.7m)

Depreciation and Amortization

3.0k

Accounts Payable

1.2m5.4m

Cash From Operating Activities

(4.2m)(10.9m)
show all
USDFY, 2019

Financial Leverage

-0.1 x
Show all financial metrics

Taysha Gene Therapies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about our premium products
SecurityScorecard logo

Taysha Gene Therapies Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Taysha Gene Therapies Online and Social Media Presence

Taysha Gene Therapies's Trends

Embed Graph

Taysha Gene Therapies News and Updates

August 01, 2022

Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET
July 06, 2022

Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022

President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday,…
June 13, 2022

Taysha Gene Therapies Announces Annual Stockholder Meeting

The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
May 16, 2022

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022
May 11, 2022

Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and…
May 10, 2022

Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy

DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and…
Show more

 Taysha Gene Therapies Frequently Asked Questions

  • When was Taysha Gene Therapies founded?

    Taysha Gene Therapies was founded in 2020.

  • Who are Taysha Gene Therapies key executives?

    Taysha Gene Therapies's key executives are RA Session II, Phillip B. Donenberg and Kamran Alam.

  • Who are Taysha Gene Therapies competitors?

    Competitors of Taysha Gene Therapies include Voyager Therapeutics, Passage Bio and Lacerta Therapeutics.

  • Where is Taysha Gene Therapies headquarters?

    Taysha Gene Therapies headquarters is located at 3000 Pegasus Park Dr Suite 1430, Dallas.

  • Where are Taysha Gene Therapies offices?

    Taysha Gene Therapies has an office in Dallas.

  • How many offices does Taysha Gene Therapies have?

    Taysha Gene Therapies has 1 office.